TSTickerStarGet alerts

STRO 10-Q filed 2026-11-12 | Key takeaways

STRO filed its 10-Q; the most relevant disclosure change is reduced Restructuring and Related Costs: Restructuring costs declined to $16K in Q3 2026 from $9.6M in Q3 2025, reflecting completion of the March and September 2025 Restructuring Plans that reduced workforce by approximately two-thirds and deprioritized the luvelta (STRO-002) program. Customer concentration: Astellas Pharma Inc. represented 99.5% of revenue; Astellas Pharma Inc. represented 99.2% of revenue.

Share this story

Key takeaways

  • Revenue concentration: Astellas represented approximately 99.5% of Q3 2026 revenue at $9.1M; Vaxcyte contributed $23K

  • Net loss narrowed 45% YoY in Q3 to $31.5M versus $56.9M, driven by $16.4M reduction in R&D expenses following restructuring

  • YTD net loss improved 25% to $108.5M from $144.3M; YTD revenue fell 63% primarily due to $56.4M Ipsen revenue in prior-year period

  • Astellas milestone: Company earned $10M contingent payment in Q3 2026 for dosing first subject in Phase 1 trial for second target program

  • Restructuring costs reduced to $16K in Q3 2026 from $9.6M in Q3 2025 as deprioritization of luvelta program winds down

  • Non-cash interest expense on deferred royalty obligation increased to $10.2M in Q3 2026 from $9.7M in Q3 2025; balance stands at $249.3M

  • Accounts receivable increased to $12.8M from $4.0M at year-end 2025, reflecting timing of milestone billings from Astellas

Key metrics

Total RevenueQ3 2026
$9.1 million-6%
Total RevenueNine months ended September 30, 2026
$33.5 million-63%
Net LossQ3 2026
$-31.5 million-45%
Net LossNine months ended September 30, 2026
$-108.5 million-25%
Net Loss Per Share (Basic and Diluted)Q3 2026
$-1.90-71%
Cash Used in Operating ActivitiesNine months ended September 30, 2026
$-103.0 million-32%

Customer concentration

Astellas Pharma Inc.Q3 2026
99.5%Share of revenue
Astellas Pharma Inc.Nine months ended September 30, 2026
99.2%Share of revenue

Disclosure changes

  • Restructuring and Related Costs

    Restructuring costs declined to $16K in Q3 2026 from $9.6M in Q3 2025, reflecting completion of the March and September 2025 Restructuring Plans that reduced workforce by approximately two-thirds and deprioritized the luvelta (STRO-002) program.

    The near-complete elimination of restructuring charges indicates the company has largely completed its organizational restructuring and cost reduction initiatives.
  • Deferred Royalty Obligation

    The deferred royalty obligation related to the sale of future Vaxcyte royalties increased to $249.3M as of September 30, 2026 from $219.5M at year-end 2025, reflecting $29.5M in non-cash interest expense recognized in the nine-month period using an effective interest rate of 16.62%.

    This non-cash liability represents significant future obligation; the imputed interest rate of 16.62% reflects Blackstone's required returns and will continue to accrete until Vaxcyte royalties are actually paid.
  • Accounts Receivable

    Accounts receivable increased significantly to $12.8M as of September 30, 2026 from $4.0M at year-end 2025, driven by the $10M Astellas milestone earned in Q3 2026 for dosing first subject in Phase 1 trial for the second target program.

    The tripling of accounts receivable reflects milestone timing and higher billed revenue, though collection risk appears limited given the collaboration partner profile.
  • Revenue Recognition - Astellas FTE Estimate Change

    In Q3 2026, the company increased its estimate of total FTE effort required to complete remaining research and development activities under the Astellas Agreement, resulting in a $5.7M downward cumulative catch-up adjustment reducing revenue, partially offset by a $9.2M positive catch-up from the Q3 2026 milestone.

    The increased FTE estimate suggests higher remaining costs to fulfill Astellas obligations, reducing near-term revenue recognition despite milestone achievements.
  • Research and Development Expense

    R&D expenses decreased 41% to $23.5M in Q3 2026 from $39.9M in Q3 2025, driven by $9.8M reduction in outside services, $3.7M in personnel-related expenses, and $2.6M in allocated facilities costs following the restructuring.

    The significant R&D reduction reflects the strategic shift away from late-stage clinical programs toward preclinical ADC pipeline (STRO-004, STRO-006, STRO-227).
  • Common Stock and Equity Structure

    Common shares outstanding increased to 16.6M as of September 30, 2026 from 8.6M at year-end 2025, primarily due to the February 2026 underwritten offering of 7.9M shares at $13.98 per share, partially offset by the December 2025 1-for-10 reverse stock split.

    The February 2026 equity raise of approximately $110M gross proceeds extended the company's cash runway but significantly diluted existing shareholders.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow STRO in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert